Gilead to be awarded attorney fees after Merck patent battle
The US District Court for the Northern District of California decided yesterday, August 11, that Gilead should be entitled to attorneys’ fees following a lawsuit in which Merck was found guilty of misconduct.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
14 April 2026 A US district court has allowed key elements of the generic drugmaker’s case against a rival to move forward, while drawing clear limits on how far the complaint can reach.
13 April 2026 The US tech company targets a disgruntled ex-employee for threatening to sell its trade secrets if he does not receive an “unreasonable fee”.
10 April 2026 The 2026 panel has been chosen. With judges from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron and law firms such as White & Case and Arnold & Porter, here’s who will be deciding this year’s winners.